Page last updated: 2024-12-09

1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea is a **small molecule** with potential therapeutic applications.

**Structure and Properties:**

* **Molecular Formula:** C14H10F2N4OS
* **Molecular Weight:** 320.3 g/mol
* **Appearance:** Typically a white or off-white solid.

**Why it's Important for Research:**

This molecule is particularly interesting due to its **structural features** and potential **biological activity**. Here's a breakdown:

* **Thiadiazole Ring:** The 1,3,4-thiadiazole ring system is known to be present in many biologically active compounds, particularly those with **anti-inflammatory, antimicrobial, and anti-cancer properties**.
* **Fluorophenyl Substituents:** The presence of two fluorophenyl groups on the thiadiazole ring is likely to influence the compound's **pharmacokinetic properties**, such as absorption, distribution, metabolism, and excretion (ADME), potentially improving its therapeutic efficacy.
* **Urea Linkage:** The urea linkage is a common structural motif found in many **drugs** and **pharmaceuticals**. It can contribute to the compound's **binding affinity** to target molecules and enhance its **bioavailability**.

**Potential Therapeutic Applications:**

Researchers are investigating the potential of this molecule for a range of therapeutic applications, including:

* **Anti-inflammatory activity:** Due to the presence of the thiadiazole ring, this compound might show promise as an anti-inflammatory agent.
* **Antimicrobial activity:** The thiadiazole ring has also been associated with antimicrobial properties.
* **Anti-cancer activity:** The molecule's structure could potentially make it effective against certain types of cancer cells.

**Ongoing Research:**

Currently, research is focused on:

* **Synthesizing and characterizing the molecule.**
* **Evaluating its biological activity in various in vitro and in vivo models.**
* **Optimizing its pharmacokinetic properties and potential therapeutic applications.**

**Note:** It's crucial to remember that this is a research compound. While it shows promising potential, further research is necessary to fully understand its properties and safety profile before any clinical applications.

Cross-References

ID SourceID
PubMed CID1390940
CHEMBL ID1595919
CHEBI ID109524

Synonyms (17)

Synonym
HMS2587G03
smr000268970
n-(2-fluorophenyl)-n'-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea
MLS000666041
STK100482
1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea
OPREA1_529881
CHEBI:109524
NCGC00240960-01
AKOS005748373
AKOS005396389
1-(2-fluorophenyl)-3-[(2e)-5-(2-fluorophenyl)-1,3,4-thiadiazol-2(3h)-ylidene]urea
STL148787
AB00106412-01
CHEMBL1595919
cambridge id 6379052
Q27188672
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
acid sphingomyelinaseHomo sapiens (human)Potency12.589314.125424.061339.8107AID504937
Nrf2Homo sapiens (human)Potency5.37410.09208.222223.1093AID624171; AID651593
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency5.80240.004110.890331.5287AID504467
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency4.46680.28189.721235.4813AID2326
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency2.51190.01262.451825.0177AID485313
ras-related protein Rab-9AHomo sapiens (human)Potency1.99530.00022.621531.4954AID485297
survival motor neuron protein isoform dHomo sapiens (human)Potency5.62340.125912.234435.4813AID1458
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's5 (62.50)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.17 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]